1. Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia

   • Aziz Nazha
   • Mrinal M. Patnaik

   Myelodysplastic Syndromes (M Savona, Section Editor) 31 July 2018 Pages: 341 - 347

   

2. Updates on Circulating Tumor DNA Assessment in Lymphoma

   • Justin M. Darrah
   • Alex F. Herrera

   B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor) 23 August 2018 Pages: 348 - 355

3. Small-Molecule Inhibitors for the Treatment of Diffuse Large B Cell Lymphoma

   • Joanna Rhodes
   • Daniel J. Landsburg

   B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor) 15 August 2018 Pages: 356 - 368

4. Emerging EZH2 Inhibitors and Their Application in Lymphoma

   • Jennifer K. Lue
   • Jennifer E. Amengual

   B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor) 15 August 2018 Pages: 369 - 382

   

5. Strategies for Predicting Response to Checkpoint Inhibitors

   • Roberta Zappasodi
   • Jedd D. Wolchok
   • Taha Merghoub

   CART and Immunotherapy (M Ruella, Section Editor) 29 August 2018 Pages: 383 - 395

   

6. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease

   • Katherine C. Pehlivan
   • Brynn B. Duncan
   • Daniel W. Lee

   Acute Lymphocytic Leukemias (K Ballen and M Keng, Section Editors) 17 August 2018 Pages: 396 - 406

7. Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis

   • John H. Baird
   • Jason Gotlib

   Myeloproliferative Neoplasms (B Stein, Section Editor) 28 August 2018 Pages: 407 - 416